The presence of epidermal growth factor receptor (EGFR) mutations is well known to be a predictive marker for response to tyrosine kinase inhibitors (TKIs) in advanced non-small cell lung cancer (NSCLC) [1]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.